Catalent Announces Global Alliance with PAREXEL to Streamline Clinical Trial Material Supply Chain Process

Catalent Pharma SolutionsPatricia McGee, 732-537-6407

Catalent Pharma Solutions, a world industry leader in drug development and advanced delivery technologies, today announced the establishment of a global alliance with PAREXEL International Corporation to help streamline the clinical trial supply process. The result of years of collaboration, the alliance will provide a seamless, fully integrated service offering to ensure the timely and efficient delivery of clinical trial materials.

“As clinical trials become more complex, we feel it is imperative to help sponsors devise supply strategies and organize consistent manufacturing, packaging, and delivery of trial-related supplies to locations around the world,” stated Gerry Hepburn, Chief Operating Officer, Vice President and General Manager of Clinical Supply Services at Catalent. “PAREXEL, with its extensive and unparalleled track record in clinical development, is the ideal partner for Catalent in this alliance, which will enable our customers to compete more effectively in the global marketplace.”

“One of the most important steps in creating a strong, efficient clinical trial material supply chain is selecting a partner with innovative clinical packaging solutions and established global operations to oversee and coordinate all aspects of each critical supply chain stage,” commented Kurt Norris, Corporate Vice President, Clinical Logistics Services, PAREXEL. “In establishing this alliance with Catalent, we have chosen a partner that is uniquely positioned to help biopharmaceutical companies reach critical development milestones through more efficient delivery of clinical trial supplies.”

The alliance will provide fully integrated services and technologies across the entire clinical trial material supply chain spectrum, supporting all supply aspects in clinical development programs including:

The establishment of this alliance follows Catalent’s February 2012 acquisition of the Clinical Trial Supplies business of Aptuit Inc., which transformed Catalent into the #2 global provider of clinical supply solutions, and enhanced Catalent’s leading global position in development solutions and advanced delivery technologies for drugs, biologics, and consumer health products.

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit .

more products. better treatments. reliably supplied.™

PAREXEL International Corporation is a leading global bio/pharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting, and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement. Perceptive Informatics, Inc., a subsidiary of PAREXEL, provides advanced technology solutions, including medical imaging, to facilitate the clinical development process. Headquartered near Boston, Massachusetts, PAREXEL operates in 70 locations throughout 51 countries around the world, and has approximately 12,695 employees. For more information about PAREXEL International, visit .

Suggested Articles

Dupixent has been posting strong sales growth for Sanofi, and now the drugmaker has a third FDA indication to keep the momentum going.

Novartis has found itself caught up in a controversy about ingredients shipped to Syria that critics say could have been used to make sarin gas. 

AbbVie made a major splash Tuesday with its proposed $63 billion buyout of Allergan. But analysts and investors were hardly impressed.